Hemodialysis

Baxter Reports Third-Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Optical, Medical Supplies, General Health, Health, Medical Devices, Health Technology, Baxter, Warburg Pincus, Tazobactam, BVLOS drone medical delivery trials in India, Piperacillin, Growth, EPS, Risk, BPS, Advent International, Medicine, Breakout Labs, EMR, Eye, Patient, Peritoneal dialysis, CDT, Pharmaceutical industry, Cassette tape, Fine chemical, Hemodialysis, Medication

Under the terms of the definitive agreement, Baxter received total proceeds of $4.25 billion, subject to adjustment for specified items.

Key Points: 
  • Under the terms of the definitive agreement, Baxter received total proceeds of $4.25 billion, subject to adjustment for specified items.
  • Baxter currently expects the Kidney Care spinoff to occur by July 2024 or earlier, subject to the satisfaction of customary conditions.
  • Baxter expects sales growth from continuing operations of 1% to 2% on a reported basis and approximately 1% on a constant currency basis.
  • A webcast of Baxter’s third-quarter 2023 conference call for investors can be accessed live from a link on the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on Nov. 2, 2023.

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Frankfurt Stock Exchange, Patient, Hemofiltration, Research, FME, Intelligence, III, HDF, Assessment of kidney function, AVF, Big data, Fatigue, HD, American Society of Nephrology, Saskatchewan River Sturgeon Management Board, Arteriovenous fistula, FX, Health, Society, Artificial intelligence, Dialysis, PO4, PSM, COVID-19, ASN, Machine learning, Congress, Fresenius Medical Care, FKC, RBV, Creatinine, Scientific Committee on Oceanic Research, FMS, Peritoneum, IDS, Data science, Pharmaceutical industry, Medical device, Hemodialysis, Nephrology

Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.

Key Points: 
  • Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.
  • Scientific and medical experts from across Fresenius Medical Care will present research related to many important topics in kidney disease care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Global Dialysis Market Set for Impressive Growth, Projected to Reach US$107.96 Billion by 2023 with a Strong CAGR of 4.80% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Health, Medical Devices, Diabetes, Hospitals, Managed Care, General Health, Biotechnology, Kidney, Waste, Incidence, Kidney failure, Equipment, Prevalence, Co-production (public services), Chronic kidney disease, Dialysis, Growth, COVID-19, Blood, Kidney disease, CKD, ESRD, Safety, Peritoneal dialysis, Video game, Medical device, Patient, Hemodialysis

The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.

Key Points: 
  • The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.
  • The services segment currently holds the largest market share, while consumables are anticipated to exhibit the highest growth with a significant CAGR.
  • By Type: The global dialysis market is segmented into Hemodialysis and Peritoneal Dialysis.
  • The global dialysis market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
ISN, Legion, SFD, Health care, Hemodialysis, American Society of Nephrology, Children's Organ Transplant Association, Quality of life, Society, International Society of Nephrology, Dialysis, Growth, Legion of Honour, MHRA, ASN, Risk, Kidney disease, EDTA, Fresenius Medical Care, International Society, Pennsylvania Convention Center, Patient, Pharmaceutical industry, Nursing, Nephrology

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
ISN, Legion, SFD, Health care, Hemodialysis, American Society of Nephrology, Children's Organ Transplant Association, Quality of life, Society, International Society of Nephrology, Dialysis, Growth, Legion of Honour, MHRA, ASN, Risk, Kidney disease, EDTA, Fresenius Medical Care, International Society, Pennsylvania Convention Center, Patient, Pharmaceutical industry, Nursing, Nephrology

GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.

Key Points: 
  • GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
  • Professor Canaud is a leading authority on kidney disease and dialysis.
  • Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
  • Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.

Florida Dialysis Centers Market Size, Share & Trends Analysis Report 2023: A $1.3 Billion Market by 2030 - Escalating Demand for Dialysis Units Propelling Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Medical Devices, Health, Arteriovenous, ESRD, American Kidney Fund, Prevalence, Kidney, COVID-19, Research, History, Hemodialysis, USD, Dialysis, Medicare, Hospital, Peritoneal dialysis, Investment, Patient, DaVita Inc., Growth, Chronic kidney disease, CKD, SNF, Fistula, Medical device, Pharmaceutical industry

The "Florida Dialysis Centers Market Size, Share & Trends Analysis Report By Modality (In-Center, In-Home, SNF-based), By Dialysis Type (Hemodialysis, Peritoneal Dialysis), By Facility Type, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Florida Dialysis Centers Market Size, Share & Trends Analysis Report By Modality (In-Center, In-Home, SNF-based), By Dialysis Type (Hemodialysis, Peritoneal Dialysis), By Facility Type, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to the American Kidney Fund, Florida is home to approximately 48,215 individuals grappling with End-Stage Renal Disease (ESRD).
  • The escalating demand for dialysis units across the state of Florida emerges as a pivotal factor expected to propel market growth in the coming years.
  • As of April 2023, DaVita owns or manages more than 200 outpatient dialysis centers in Florida

Humacyte Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Monday, August 14, 2023
Infection, Chin Na, JDRF, Insulin, Accident, Diabetes, Conference call, Survival, Trauma, Research, Completeness, Trauma center, Fistula, Sale, Military personnel, Kidney disease, Dialysis, Regenerative medicine, Literature, Polytetrafluoroethylene, Injury, Animal, Patient, Level, HUMA, Primate, Gunshot, Hemodialysis, BVP, FDA, HAV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Conference, Food, Safety, Pharmaceutical industry, Video game, Reinsurance, Journal

DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • ET today -
    DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments.
  • Results from the V005 trial are expected in the third quarter of 2023 and are intended to support a BLA filing for the vascular trauma indication with the FDA planned for the fourth quarter 2023.
  • There was no revenue for the second quarter of 2023 and six months ended June 30, 2023.
  • Total net cash used was $35.2 million for the second quarter of 2023, compared to $36.5 million for the second quarter of 2022, with the current-year decrease in cash used related to proceeds from our Oberland funding agreement.

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Chronic kidney disease, Medicine, Health care, Quality of life, Medication, CSL Vifor, Hemodialysis, Medicines and Healthcare products Regulatory Agency, Patient, Itch, Therapy, CKD, NICE, MHRA, National Institute for Health and Care Excellence, Nursing, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.

Key Points: 
  • The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • "The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK," said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • "We look forward to continue working with the National Health Service to ensure access to this important medicine for patients as quickly as possible."
  • "Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed."

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Chronic kidney disease, Medicine, Health care, Quality of life, Medication, CSL Vifor, Hemodialysis, Medicines and Healthcare products Regulatory Agency, Patient, Itch, Therapy, CKD, NICE, MHRA, National Institute for Health and Care Excellence, Nursing, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.

Key Points: 
  • The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • "The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK," said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • "We look forward to continue working with the National Health Service to ensure access to this important medicine for patients as quickly as possible."
  • "Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed."

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Medicine, Health care, Quality of life, CSL Vifor, Hemodialysis, Patient, Therapy, CKD, NICE, MHRA, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

Key Points: 
  • ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
  • The decision follows authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • “The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK,” said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • “We now have an option to help reduce the burden of CKD-related itch.”
    MHRA approval and the NICE recommendation were supported by positive data from two pivotal phase-III trials – KALM-1, conducted in the U.S. (New England Journal of Medicine 2020; 382:222-232), and the global KALM-2, as well as supportive data from an additional 32 clinical studies.